Kyme Pierre 4
4 · Armata Pharmaceuticals, Inc. · Filed Feb 7, 2025
Insider Transaction Report
Form 4
Kyme Pierre
Chief Business Officer
Transactions
- Award
Stock Options (Right to Buy)
2025-02-05+100,000→ 100,000 totalExercise: $2.04Exp: 2035-02-05→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028 and 2029, in each case subject to continuous service through the applicable vesting date.